US 12,065,667 B2
Modified Cpf1 MRNA, modified guide RNA, and uses thereof
Yizhou Dong, Dublin, OH (US); and Bin Li, Columbus, OH (US)
Assigned to OHIO STATE INNOVATION FOUNDATION, Columbus, OH (US)
Appl. No. 16/094,062
Filed by OHIO STATE INNOVATION FOUNDATION, Columbus, OH (US)
PCT Filed Apr. 14, 2017, PCT No. PCT/US2017/027762
§ 371(c)(1), (2) Date Oct. 16, 2018,
PCT Pub. No. WO2017/181107, PCT Pub. Date Oct. 19, 2017.
Claims priority of provisional application 62/400,843, filed on Sep. 28, 2016.
Claims priority of provisional application 62/385,471, filed on Sep. 9, 2016.
Claims priority of provisional application 62/328,741, filed on Apr. 28, 2016.
Claims priority of provisional application 62/323,683, filed on Apr. 16, 2016.
Prior Publication US 2020/0172935 A1, Jun. 4, 2020
Int. Cl. C12N 15/67 (2006.01); C12N 9/22 (2006.01); C12N 15/10 (2006.01); C12N 15/85 (2006.01); C12N 15/90 (2006.01)
CPC C12N 15/907 (2013.01) [C12N 9/22 (2013.01); C12N 15/102 (2013.01); C12N 15/67 (2013.01); C12N 15/85 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/322 (2013.01); C12N 2310/335 (2013.01)] 6 Claims
OG exemplary drawing
 
1. A genome editing system having enhanced gene editing efficiency comprising:
a) a guide RNA that hybridizes with a target sequence of a DNA molecule in a eukaryotic cell that contains the DNA molecule, and
b) an mRNA encoding a CRISPR from Prevotella and Francisella 1 (“Cpf1”) protein;
wherein the guide RNA comprises five 2′fluoro (2′F) ribose at the 3′termini (cr3′5), and wherein the mRNA encoding the Cpf1 protein is fully substituted with pseudouridine (Ψ).